Client News

RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results

Abivax’s phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium 2022

Avisa Diagnostics Reports on Status of Interim Filings

sterna biologicals receives approval for innovative phase II a study design in asthma combining a novel antisense-based treatment with a digital therapy

Marinomed Biotech AG Reports Significant Revenue Growth for the First 9 Months 2021

EsoCap secures new funding

InflaRx to Present at H.C. Wainwright 7th Annual Israel Conference

Secarna Pharmaceuticals and Achilles Therapeutics sign research, option and license agreement to develop optimized T cell therapies

MagForce AG: MagForce USA, Inc. has Received FDA’s Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System

InflaRx Reports Third Quarter 2021 Financial & Operating Results